GlassScriptPhysician profile
Kenneth D Owen
NPI 1922117191
$6,251.13
in general payments reported to CMS, 2019-2025
24 companies · $5,442 in 2025
The $5,442 reported for 2025 was more than what 92% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $107 · 2021: $41.88 · 2022: $77.34 · 2023: $172 · 2024: $225 · 2025: $5,442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $4,782 · Food and Beverage: $1,058.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $4,781.51 |
| Food and Beverage | $1,057.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $4,781.51 | 2025 | Evis Exera III Colonovideoscope, Evis Exera III Video System Center, Evis Exera III Xenon Light Source |
| E.R. Squibb & Sons, L.L.C. | $307.42 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $276.05 | 2020-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $106.67 | 2019-2024 | Xarelto |
| Philips North America LLC | $101.14 | 2023-2025 | (Ck4) Mcot, Event |
| Bayer Healthcare Pharmaceuticals INC. | $82.56 | 2025 | |
| Sanofi-Aventis U.S. LLC | $63.18 | 2020-2024 | |
| Novo Nordisk INC | $62.53 | 2024-2025 | Wegovy |
| Heartflow, INC. | $48.36 | 2025 | |
| Atricure, INC. | $43.53 | 2022 | |
| Circassia INC. | $42.51 | 2019 | |
| Pfizer INC. | $40.98 | 2019-2025 | |
| Edwards Lifesciences Corporation | $33.94 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Alnylam Pharmaceuticals INC. | $29.97 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.91 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $28.74 | 2019-2020 | |
| Esperion Therapeutics, INC. | $27.33 | 2025 | Nexletol |
| Abiomed | $25.95 | 2025 | |
| Baxter Healthcare | $24.56 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Abbvie INC. | $23.21 | 2020 | |
| Lantheus Medical Imaging, INC. | $21.78 | 2025 | |
| Novartis Pharmaceuticals Corporation | $20.38 | 2025 | |
| Genentech USA, INC. | $16.82 | 2019 | |
| Optinose US, INC. | $13.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Owen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.